secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063735
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health Q3 revenue down 41% YoY to $282K; gross profit up 71% to $108K
---------------------------------------------------------------------------

- Net loss of $1.8M narrowed from $2.6M in Q3 2022; operating expenses fell 30% to $1.9M.
- Gross margin improved to 38% from 13% YoY on price increases and supply-chain optimization.
- Cash and equivalents totaled $5.2M as of Sept 30, 2023.
- Announced partnerships with InStep Health and Amerisource Bergen; NASDAQ compliance regained after reverse stock split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023063735/0000950170-23-063735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023063735/tivc-20231114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer